EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 27 / No 10 (Octobre 2011) Med Sci (Paris), 27 10 (2011) 833-841 References
Free Access
Issue
Med Sci (Paris)
Volume 27, Number 10, Octobre 2011
Page(s) 833 - 841
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20112710011
Published online 21 October 2011
  1. Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992 ; 46 : 473–484. [Google Scholar]
  2. Abes R, Gelize E, Fridman WH, et al. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010 ; 116 : 926–934. [CrossRef] [PubMed] [Google Scholar]
  3. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007 ; 13 : 5133–5143. [CrossRef] [PubMed] [Google Scholar]
  4. Bodmer A, Goetsch L, Favet L, et al. Anticorps et tumeurs solides : cibles établies et pistes prometteuses. Med Sci (Paris) 2009 ; 25 : 1090–1098. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Pages F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors : a prognostic factor that should not be ignored. Oncogene 2010 ; 29 : 1093–1102. [CrossRef] [PubMed] [Google Scholar]
  6. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009 ; 21 : 233–240. [CrossRef] [PubMed] [Google Scholar]
  7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010 ; 363 : 411–422. [CrossRef] [PubMed] [Google Scholar]
  8. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011 ; 364 : 2119–2127. [CrossRef] [PubMed] [Google Scholar]
  9. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011 ; 29 : 2787–2794. [CrossRef] [PubMed] [Google Scholar]
  10. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 ; 364 : 2517–2526. [Google Scholar]
  11. Atkins MB. Treatment selection for patients with metastatic renal cell carcinoma : identification of features favoring upfront IL-2-based immunotherapy. Med Oncol 2009 ; 26 (suppl 1): 18–22. [CrossRef] [PubMed] [Google Scholar]
  12. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001 ; 19 : 3477–3482. [PubMed] [Google Scholar]
  13. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 ; 10 : 909–915. [Google Scholar]
  14. Haicheur N, Escudier B, Dorval T, et al. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 2000 ; 119 : 28–37. [CrossRef] [PubMed] [Google Scholar]
  15. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2. Based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996 ; 14 : 1697–1703. [PubMed] [Google Scholar]
  16. Derhovanessian E, Adams V, Hahnel K, et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009 ; 125 : 1372–1379. [CrossRef] [PubMed] [Google Scholar]
  17. Marshall M, Ribas A, Huang B. Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. ASCO meeting abstracts, June 14th, 2010. J Clin Oncol 2010 ; 28 : 2609 (abstract). [CrossRef] [Google Scholar]
  18. Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010 ; 70 : 6171–6180. [CrossRef] [PubMed] [Google Scholar]
  19. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009 ; 27 : 2645–2652. [CrossRef] [PubMed] [Google Scholar]
  20. Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010 ; 138 : 1429–1440. [CrossRef] [PubMed] [Google Scholar]
  21. Gajewski TF, Fuertes M, Spaapen R, et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2010 ; 23 : 286–292. [CrossRef] [PubMed] [Google Scholar]
  22. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005 ; 201 : 241–248. [CrossRef] [PubMed] [Google Scholar]
  23. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003 ; 9 : 998–1008. [PubMed] [Google Scholar]
  24. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Exp Rev Vaccines 2008 ; 7 : 889–893. [CrossRef] [Google Scholar]
  25. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009 ; 361 : 1838–1847. [CrossRef] [PubMed] [Google Scholar]
  26. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008 ; 8 : 351–360. [CrossRef] [PubMed] [Google Scholar]
  27. Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009 ; 27 : 3036–3043. [CrossRef] [PubMed] [Google Scholar]
  28. Brichard VG, Lejeune D. GSK’s antigen-specific cancer immunotherapy programme : pilot results leading to Phase III clinical development. Vaccine 2007 ; 25 (suppl 2): B61–B71. [CrossRef] [PubMed] [Google Scholar]
  29. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005 ; 23 : 7536–7545. [CrossRef] [PubMed] [Google Scholar]
  30. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010 ; 102 : 1388–1397. [CrossRef] [PubMed] [Google Scholar]
  31. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010 ; 28 : 1099–1105. [CrossRef] [PubMed] [Google Scholar]
  32. van Baren N, Bonnet MC, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005 ; 23 : 9008–9021. [CrossRef] [PubMed] [Google Scholar]
  33. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006 ; 354 : 709–718. [CrossRef] [PubMed] [Google Scholar]
  34. Bouwhuis MG, Ten Hagen TL, Suciu S, et al. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2010 ; 23 : 170–176. [CrossRef] [Google Scholar]
  35. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005 ; 23 : 6043–6053. [CrossRef] [PubMed] [Google Scholar]
  36. Nelson BH. CD20+ B cells : the other tumor-infiltrating lymphocytes. J Immunol 2010 ; 185 : 4977–4982. [CrossRef] [PubMed] [Google Scholar]
  37. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008 ; 3 : 735–744. [CrossRef] [PubMed] [Google Scholar]
  38. Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008 ; 31 : 101–112. [CrossRef] [PubMed] [Google Scholar]
  39. Leibundgut-Landmann S, Osorio F, Brown GD, et al. Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 2008 ; 112 : 4971–4980. [CrossRef] [PubMed] [Google Scholar]
  40. Berraondo P, Nouze C, Preville X, et al. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007 ; 67 : 8847–8855. [CrossRef] [PubMed] [Google Scholar]
  41. Adotevi O, Vingert B, Freyburger L, et al. B Subunit of Shiga toxin-based vaccines synergize with (alpha)-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007 ; 179 : 3371–3379. [PubMed] [Google Scholar]
  42. Vingert B, Adotevi O, Patin D, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006 ; 36 : 1124–1135. [CrossRef] [PubMed] [Google Scholar]
  43. Darrasse-Jeze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009 ; 119 : 2648–2662. [PubMed] [Google Scholar]
  44. Welters MJ, Kenter GG, van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010 ; 107 : 11895–11899. [CrossRef] [Google Scholar]
  45. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010 ; 207 : 2175–2186. [CrossRef] [PubMed] [Google Scholar]
  46. Derre L, Rivals JP, Jandus C, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010 ; 120 : 157–167. [CrossRef] [PubMed] [Google Scholar]
  47. Badoual C, Bouchaud G, Agueznay Nel H, et al. The soluble alpha chain of interleukin-15 receptor : a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008 ; 68 : 3907–3914. [CrossRef] [PubMed] [Google Scholar]
  48. Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010 ; 120 : 1285–1297. [CrossRef] [PubMed] [Google Scholar]
  49. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010 ; 140 : 798–804. [CrossRef] [PubMed] [Google Scholar]
  50. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008 ; 8 : 59–73. [CrossRef] [PubMed] [Google Scholar]
  51. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009 ; 114 : 589–595. [CrossRef] [PubMed] [Google Scholar]
  52. Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999 ; 5 : 2963–2970. [PubMed] [Google Scholar]
  53. Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010 ; 33 : 991–998. [CrossRef] [PubMed] [Google Scholar]
  54. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009 ; 15 : 2148–2157. [CrossRef] [PubMed] [Google Scholar]
  55. Huang KW, Wu HL, Lin HL, et al. Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc Natl Acad Sci USA 2010 ; 107 : 14769–14774. [Google Scholar]
  56. Abès R, Dutertre CA, Teillaud JL. Les anticorps : mieux les connaître pour mieux s’en servir. Med Sci (Paris) 2009 ; 25 : 1011–1019. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  57. Robert C, Mateus C. Anticorps anti–CTLA 4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  58. Apetoh L, Ghiringhelli F, Zitvogel L. La calréticuline détermine l’immunogénicité de la chimiothérapie et de la radiothérapie antitumorales. Med Sci (Paris) 2007 ; 23 : 257–258. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  59. Rousseaux S, Reynoird N, Gaucher J, Khochbin S. L’intrusion des régulateurs de l’épigénome mâle dans les cellules somatiques cancéreuses. Med Sci (Paris) 2008 ; 24 : 735–741. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  60. Olive D, le Thi S, Xerri L, et al. Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire. Med Sci (Paris) 2011 ; 27 : 842–849. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.